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Aberrant autonomic signaling is being increasingly recognized as an important symptom
in neuromuscular disorders. The δ-sarcoglycan-deﬁcient BIO TO-2 hamster is recognized
as a good model for studying mechanistic pathways and sequelae in muscular dystrophy
and heart failure, including autonomic nervous system (ANS) dysfunction. Recent studies
using theTO-2 hamster model have provided promising preclinical results demonstrating
the efﬁcacy of gene therapy to treat skeletal muscle weakness and heart failure. Methods
to accelerate preclinical testing of gene therapy and new drugs for neuromuscular dis-
eases are urgently needed.The purpose of this investigation was to demonstrate a rapid
non-invasivescreenforcharacterizingtheANSimbalanceindystrophicTO-2hamsters.Elec-
trocardiograms were recorded non-invasively in conscious ∼9-month old TO-2 hamsters
(n=10) and non-myopathic F1B control hamsters (n=10). Heart rate was higher in TO-2
hamsters than controls (453±12bpm vs. 311±25bpm, P<0.01).Time domain heart rate
variability, an index of parasympathetic tone, was lower inTO-2 hamsters (12.2±3.7bpm
vs. 38.2±6.8, P<0.05), as was the coefﬁcient of variance of the RR interval (2.8±0.9%
vs. 16.2±3.4%, P<0.05) compared to control hamsters. Power spectral analysis demon-
strated reduced high frequency and low frequency contributions, indicating autonomic
imbalance with increased sympathetic tone and decreased parasympathetic tone in dys-
trophic TO-2 hamsters. Similar observations in newborn hamsters indicate autonomic
nervous dysfunction may occur quite early in life in neuromuscular diseases. Our ﬁnd-
ings of autonomic abnormalities in newborn hamsters with a mutation in the δ-sarcoglycan
gene suggest approaches to correct modulation of the heart rate as prevention or therapy
for muscular dystrophies.
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INTRODUCTION
Neuromusculardiseases,routinelyconsideredwithregardtomus-
cle weakness, frequently affect the heart and the cardiovascular
system.Aberrant autonomic signaling is being increasingly recog-
nized as an important symptom in a variety of clinically deﬁned
neuromuscular disorders (Rakocevi´ c-Stojanovi´ c et al.,2007; Poli-
tano et al., 2008; Inoue et al., 2009; Della Marca et al., 2010).
Patients with Duchenne muscular dystrophy, for example, often
present with tachycardia and signiﬁcant decreases in heart rate
variability(HRV;Marcelloetal.,1995;Yotsukuraetal.,1998);car-
diac failure is frequently the cause of death (Judge et al., 2011).
There is a growing number of case reports presenting cardiac
abnormalities in patients with spinal muscular atrophy (SMA;
Hachiya et al., 2005; Rudnik-Schöneborn et al., 2008), a debilitat-
ing neurological disease marked predominantly by motor neuron
death and atrophy of skeletal muscle. Cardiac muscle pathology
sometimes exceeds skeletal muscle pathology in cases of limb-
girdle muscular dystrophy (LGMD; Margeta et al., 2009). Many
neuromusculardiseasesaffectchildren.Duchenne’smusculardys-
trophy and some LGMD, childhood muscle disorders resulting
from loss of expression of sarcoglycans, are both characterized
by similar aberrant autonomic modulation of the heart in animal
models(Giudiceetal.,2000;Chuetal.,2002).Therearesomedata
that indicate that pathology that deﬁne the adult dystrophic phe-
notypeoriginateinutero (Merricketal.,2009).Here,wesoughtto
determineif thereisevidenceof autonomicnervoussystem(ANS)
abnormalities early in the life of δ-sarcoglycan-deﬁcient hamsters,
a model of LGMD characterized by deﬁnitive histopathological
and clinical sequelae of skeletal muscle pathology and heart fail-
urelateinlife(Straubetal.,1998;Xiaoetal.,2000;Zhuetal.,2005;
Kato et al.,2006; Hoshijima et al.,2011).
MATERIALS AND METHODS
ANIMALS
Male BIO F1B non-myopathic control and BIO TO-2 dystrophic
hamsters were obtained from BioBreeders, Inc., Fitchburg, MA,
USA. Handling and care of hamsters were consistent with federal
guidelinesandapprovedinstitutionalprotocols.Adultswerestud-
ied at ∼9 months,an age with established clinical and histopatho-
logical evidence of skeletal and cardiac muscle disease (Zhu et al.,
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2005; Hoshijima et al., 2011). Newborn pups were studied at ∼4
and∼11daysof age.Thedamswereremovedfromthenestsprior
to handling of the pups. A heat lamp was positioned near to a
nest to provide ambient warmth to a pup in its mother’s absence.
The time required to position a pup on the heated ECG recording
platform(LifeSpoon™,MouseSpeciﬁcs,Inc.,Boston)andacquire
the ECG signal was ∼5min,after which the pup was immediately
returned to its dam.
ECG RECORDINGS
ECGs were recorded non-invasively in conscious hamsters simi-
lar to a method described previously for mice (Chu et al., 2001).
Brieﬂy, hamsters were gently removed from their cages and posi-
tionedinsidetheECGenie™recordingenclosure(MouseSpeciﬁcs,
Inc., Boston, MA, USA) sized to comfortably accommodate adult
hamsters.Apairof silver-chlorideECGelectrodeswereembedded
intheﬂooroftheenclosureandspacedtoprovidecontactbetween
the electrodes and animals’ paws. Since even modest handling of
hamsters may induce alterations in heart rate, each hamster was
permitted to acclimatize for ∼10min prior to collection of data.
The signals were digitized at a sampling rate of 2000 samples/s.
Whenhamsterswerepositionedsuchthataforepawandhindpaw
were not uniquely in contact with one of the electrodes, the out-
put from the ampliﬁer was discarded. Only data from continuous
recordings were used in the analyses. Each signal was analyzed
using e-MOUSE™, which incorporates Fourier analyses and lin-
ear time-invariant digital ﬁltering of frequencies below 3Hz and
above100Hztominimizeenvironmentalsignaldisturbances.The
software uses a peak detection algorithm to ﬁnd the peak of the
R-waves and to calculate heart rate. Subsequently, determination
of ﬁrst and second derivatives and algebraic “if-then” search the
ECG signals for probable P-wave peaks and onset and termina-
tion of QRS complexes. The end of the T-wave of each signal was
deﬁned as the point where the signal returned to the isoelectric
line (the mean voltage between the preceding P-wave and QRS
interval). The QT intervals were rate corrected (QTc) by applica-
tion of an equation recommended for rodent electrocardiography
(Mitchell et al., 1998). The software plots its interpretation of P,
Q, R, S, and T for each beat so that spurious data resulting from
unﬁltered noise or motion artifacts may be rejected. e-MOUSE™
then calculates the mean of the ECG time intervals for each set of
waveforms. Figure1A depicts a F1B control hamster exploring an
ECGenie™ recording enclosure.
For electrocardiographic monitoring of the neonates, hamster
pups were positioned atop of the LifeSpoon™ ECG recording
module,the surface of which is embedded with two heated silver-
chloride electrodes to maintain a warmed environment similar to
that provided by the nursing mother and nest. Surprisingly, even
at ∼4 days of age, the hamster pups were initially quite ambula-
tory, but became quiescent after ∼5min at which time ∼20–30
complexes were recorded.
Measures of heart beat-to-beat variability (HRV) were deter-
mined as the SD and the coefﬁcient of variation (CV). The SD
reﬂects the dispersion about the average value for a parameter.
CV, expressed as a%, was calculated from the following equation:
100×SD/mean value. Power spectral analysis of ECG in the fre-
quency domain for analysis of HRV was accomplished using low
FIGURE1|( A )Adult (∼9 months old) F1B control hamster exploring an
ECGenie™ recording enclosure just prior to the lid being closed to prevent
escape; to the right aTO-2 hamster can be seen inside an ECG recording
enclosure.The ECG is detected passively through the underside of the
subject’s paws as it rests atop two electrodes embedded in the enclosure
ﬂoor. (B) Representative ECG signals, a subset from ∼100 continuous ECG
complexes recorded over ∼15s, acquired non-invasively from a conscious
adultTO-2 hamster.The PQRST morphology is indicated; note the high
regularity in the RR intervals in this cardiomyopathic animal.
frequency (LF) and high frequency (HF) ranges similar to those
previously published for hamsters (Giudice et al., 2000). The LF
power range was set from 0.04 to 1.0Hz,and the HF power range
was set from 1.0 to 3.0Hz.
STATISTICS
Data are presented as the mean±SE. Group means comparisons
between strains, or among strains between ages, were performed
using Student’s two-tailed t-test for unpaired observations. Dif-
ferences were considered signiﬁcant with P <0.05.
RESULTS
We recorded ECGs non-invasively in 10 conscious F1B control
hamsters and 10 TO-2 δ-sarcoglycan-deﬁcient hamsters, an ani-
mal model used routinely to test the efﬁcacy of new therapies
in treating muscular dystrophies and heart failure. A represen-
tative ECG recording from a ∼9-month old TO-2 hamster is
shown in Figure 1B, a subset of ∼100 continuous ECG com-
plexes acquired over ∼15s. Since the hamsters are conscious,
baseline artifact and noise are apparent in the unﬁltered signals.
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Yet, the P-waves and T-waves are discernible by eye and inter-
pretable by the software algorithmic processing of the signal
digitizedat2000samples/s.Anydiscontinuitiesinthesignalresult-
ing from loss of contact between the paws and the electrodes
were excluded from analysis. The hamster ECG is more typi-
cal of that of mouse and rat in that there is no separate T-
wave (Bestetti and Oliveira, 1990; Chu et al., 2001), and unlike
in guinea pigs where there is a separate T-wave (Gussak et al.,
2000).
Analyses of the digitized ECG signals demonstrated signiﬁ-
cantly higher heart rate in TO-2 dystrophic hamsters than in F1B
controls(453±12bpmvs.311±25bpm,P <0.01).Table 1 sum-
marizestheECGobservations,whichincludeshorterPRduration
and QT interval in TO-2 than in F1B hamsters. Rate corrected
QT (QTc) in TO-2 hamsters was signiﬁcantly shorter than in F1B
hamsters (59.3±0.9ms vs. 69.5±2.5ms, P <0.05).
Heart rate variability was signiﬁcantly lower in TO-2 ham-
sters compared to F1B control hamsters as reﬂected by HRV
(12.2±3.7bpmvs.38.2±6.8bpm,P <0.05)andCV(2.8±0.9%
vs. 16.2±3.4%, P <0.05; Table 1). Figure 2 illustrates RR
tachograms, or analysis of variations in the instantaneous heart
ratetimeseriesusingthebeat-to-beatRRintervals,toreﬂectHRV.
Note the lower beat-to-beat variability in the RR intervals in the
cardiomyopathic TO-2 hamster,reﬂecting the lower HRV in these
animals.
Analysis of HRV in the frequency domain further character-
ized reduced HRV in TO-2 hamsters. Fourier transformation of
the beat-to-beat interval duration series yielded power spectral
densities, from which total power, LF, and HF values were com-
puted. Total power was reduced in cardiomyopathic TO-2 ham-
sters compared to controls (3.0±1.2ms2 vs. 881.6±293.8ms2,
P<0.05). The LF component, reﬂecting mainly sympathetic
inﬂuences, was lower in TO-2 than in controls (1.2±0.6ms2
vs. 502.8±165.3ms2, P<0.05). The HF spectral component,
reﬂecting mainly parasympathetic inﬂuences, was also lower in
cardiomyopathic TO-2 than in F1B hamsters (1.6±0.6ms2 vs.
335.2±125.7ms2, P<0.05). Figure 3 illustrates the signiﬁcantly
lowerHRVrevealedbypowerspectralanalysisinTO-2dystrophic
hamsters.
Table 1 | Electrocardiographic parameters in BIO F1B and BIOTO-2
conscious hamsters.
F1B (n =10) TO-2 (n =10)
Heart rate (bpm) 311±25 453±12*
HR variability (bpm) 38.2±6.8 12.2±3.7*
CV (%) 16.2±3.4 2.8±0.9*
PR (ms) 53.8±4.2 36.8±2.1*
QRS (ms) 23.5±1.7 19.1±1.2
QT (ms) 99.3±6.2 68.5±1.9*
QTc (ms) 69.5±2.5 59.3±0.9*
Values are mean±SE.
HR var, heart rate variability; CV, coefﬁcient of variation; QTc, QT corrected for
heart rate.
*P<0.05 vs. F1B hamsters.
Reducing the spacing of the electrodes and providing heat to
the ECG recording surface enabled recording of the ECG in new-
born F1B hamsters (n =3) and TO-2 hamsters (n =4) and return
them to their dams. Figure 4A depicts a hamster pup inside the
LifeSpoon™ ECG recording chamber; Figure 4B shows represen-
tative complexes from a ∼4-day old TO-2 hamster pup. The heart
rateintheneonates,208±11bpminF1Bpupsand248±15bpm
in TO-2 pups, was signiﬁcantly lower than heart rate in the adult
hamsters (P <0.05), consistent with the relative bradycardia that
has been reported for neonatal mice (Heier et al., 2010) and rats
(HoferandReiser,1969).Heartratewassigniﬁcantlyhigher,how-
ever, in ∼4-day old TO-2 hamsters than F1B control hamsters
(P<0.05). HRV in F1B neonates was signiﬁcantly lower than in
adultF1Bhamsters(15.7±8.3bpmvs.38.2±6.8,P <0.05).HRV
FIGURE2|R Rt a c hograms, or analysis of variations in the
instantaneous heart rate time series using the beat-to-beat RR
intervals, to reﬂect heart rate variability. Beat-to-beat variability in the RR
interval durations was very low in cardiomyopathicTO-2 hamsters,
reﬂecting altered autonomic heart rate modulation in comparison to F1B
control hamsters.
FIGURE3|P o w e rspectral analysis indicated lower total power,
comprised of reduced LF (sympathetic inﬂuences) and reduced HF
(parasympathetic inﬂuences) components.These data further
characterize the abnormal autonomic balance inTO-2 dystrophic hamsters.
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FIGURE4|( A )NeonateTO-2 hamster (∼4 days old) resting on
warmed LifeSpoon™ ECG recording platform. (B) ECG tracings from
neonatal (∼4 days old) F1B control hamster. Heart rate was
signiﬁcantly higher, and heart rate variability signiﬁcantly lower, inTO-2
dystrophic hamsters, indicative of autonomic dysfunction, beginning
very early in life.
in developing TO-2 hamsters, moreover, was not different from
adult TO-2 hamsters.
Autonomic differences were also apparent by ∼11 days of age.
HRVwassigniﬁcantlylowerinTO-2hamsters(n =5)thaninF1B
hamsters (n =5; 8.8±0.9bpm vs. 16.3±3.1bpm, P<0.05) as
wasCV(5.1±0.6%vs.9.9±0.2%,P<0.05).Totalpowerandthe
LFcomponentweresigniﬁcantlylowerin∼11-dayoldTO-2ham-
sters than in F1B controls. The ratio of the LF to HF component,
a strong indicator of sympathetic tone (Mongue-Din et al.,2009),
wasalsosigniﬁcantlylowerin∼11-dayoldδ-sarcoglycan-deﬁcient
TO-2 hamsters. These data indicate that autonomic dysfunction
begins early in life in these overtly healthy animals that go on
to develop pathological evidence and clinical signs of muscular
dystrophy and heart failure.
DISCUSSION
This report describes a simple and elegant system for recording
ECGs in conscious newborn and adult hamsters; neither attach-
mentof wires,noranesthesia,norsurgicalimplantationof devices
isrequired.TheECGmeasurementsweobtainednon-invasivelyin
conscious adult hamsters are comparable to those obtained using
subcutaneously implanted electrodes (Giudice et al., 2000) and
implantable telemetry devices (Mongue-Din et al., 2009; Wang
etal.,2011).Thedataweobtainednon-invasivelyinawakeneona-
tal δ-sarcoglycan-deﬁcient TO-2 hamsters suggest that the ANS
abnormalitiesclearlyapparentinoldermoribundmyopathicTO-2
animals may actually commence very early in life.
Theδ-sarcoglycan-deﬁcientBIOTO-2hamsterisanestablished
model of human LGMD-type 2F muscular dystrophy and heart
failure. Whereas muscle weakness, predominantly affecting the
pelvic and shoulder girdles,is the characteristic feature in patients
withLGMD,cardiomyopathyisfrequentlythecauseof death.The
TO-2 hamster model recapitulates these characteristics. Pathol-
ogy has indicated damage to the intercostal muscles, proximal
limb muscles, muscles of the pelvic girdle, shoulder, gastrocne-
mius, triceps, and tibialis muscles (Straub et al., 1998; Xiao et al.,
2000;Zhuetal.,2005).Skeletalmuscleweaknessandpathologyare
alreadyevidentinTO-2animalsat∼1monthof age(Homburger,
1979; Straub et al., 1998; Hampton et al., 2011). These hamsters,
however,alsodevelopcardiacpathologyapparentafter∼3months
of age. Cardiac ﬁbrosis and calciﬁcation lead to dilation; conges-
tive heart failure is usually the cause of death in TO-2 hamsters
(Xiao et al., 2000; Zhu et al., 2005; Kato et al., 2006; Hoshijima
et al.,2011).
Healthy modulation of the heart rhythm is inﬂuenced by the
ANS, with contributions from the parasympathetic and sympa-
thetic limbs of the ANS enabling a fair amount of plasticity in
heart rate. Reduced HRV is an established marker of autonomic
dysfunction and is associated with increased mortality in patients
with heart failure. To the best of our knowledge, there are two
descriptionsof reducedHRVandautonomicdysfunctioninTO-2
hamsters. Researchers (Giudice et al., 2000) described a proce-
dure of surgical implantation of radio transmitters followed by
a recovery period to report heart rate and HRV data quite simi-
lar to the values we obtained non-invasively. They demonstrated
autonomic imbalance of cardiac control due to attenuation of
parasympathetic activity and enhanced sympathetic tone in TO-
2 hamsters in heart failure. Our observations of reductions in
the total spectral power, the LF component, and the HF compo-
nent, are in agreement with those they reported. A subsequent
study in cardiomyopathic TO-2 hamsters, also reporting similar
values for heart rate and HRV as we report here, demonstrated
that the lusitropic agent istaroxime improved cardiac function via
preservationof autonomictone(LoGiudiceetal.,2011).Changes
in autonomic modulation of the heart in TO-2 cardiomyopathic
hamsters was thought to be a reactive compensation to impaired
cardiac function (Giudice et al., 2000). Our novel observations
of autonomic dysregulation of heart rhythm in neonatal TO-2
hamsters,however,suggests that autonomic dysfunction might be
a causative factor in the etiology of skeletal and cardiac muscle
disease.
Autonomic nervous system dysfunction of the heart in TO-2
hamsters can be quickly and non-invasively quantiﬁed. To what
extent unabated sympathetic overdrive commencing early in life
contributes to the eventual demise of skeletal and cardiac muscle
remains to be determined.
ThemethodwedescribeforrecordingECGinnewbornrodents
and our observations of neonatal autonomic disturbances are of
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practical signiﬁcance in accelerating the testing of new therapeu-
tic modalities in the treatment of muscular dystrophies and heart
failure.
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